HopeStage
Back to overview

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Topics

More filters

Study design
Intervention type
Study phase
16studies shown
Showing 1-12 of 16
Drug study icon
RecruitingNCT07286175

Brenipatide added to usual care to delay relapse in bipolarity

About this title

A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)

Read the official source — NCT07286175
What is this study about?

Researchers compare brenipatide with placebo, both added to usual treatment, to find out whether it delays a new mood episode in adults with bipolarity. They monitor changes in symptoms and the safety of the added medicine.

Recruiting in Mexico
BipolarityMedication studyAges 18–75
Countries
Mexico, United States, Argentina, + 4 others
Sponsor
Eli Lilly and Company
Drug study icon
RecruitingNCT07477990

Digital CBT added to usual medication for generalized anxiety

About this titleRead the official source — NCT07477990
Official study title

Phase III, Randomized, Multicenter, Open-label Clinical Trial to Evaluate the Efficacy and Safety of the Aurora® Digital Medical Device With Conventional Drug Treatment, Compared to Conventional Drug Treatment Alone, in Adult Patients With Moderate to Severe Generalized Anxiety Disorder

Recruiting in Mexico
AnxietyMedication studyAges 18–65
Countries
Mexico
Sponsor
Psicofarma, S.A. De C.V.
Device study icon
RecruitingNCT06189690

Repetitive brain stimulation for cocaine use: blood and craving measures

About this title

Effect of HF rTMS on Serum BDNF in Cocaine Use Disorder

Read the official source — NCT06189690
Official study title

Effects of 5-Hz Repetitive Transcranial Magnetic Stimulation on Serum Brain Derived Neurotrophic Factor and Clinical Variables in Cocaine Use Disorder

Recruiting in Mexico
AddictionDevice studyAges 18–50
Countries
Mexico
Sponsor
Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente
Drug study icon
RecruitingNCT05980949

Long-term safety of KarXT for psychosis associated with Alzheimer’s disease

About this titleRead the official source — NCT05980949
Official study title

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

Recruiting in Mexico
SchizophreniaMedication studyAges 55–90
Countries
Mexico, United States, France, + 27 others
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.